Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Hybrigenics

October 7, 2008
Hybrigenics appoints Eric Castaldi to its Board of Directors
Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced today the appointment of Eric Castaldi to its Board as a non-executive independent Director. More

September 8, 2008
Hybrigenics obtains EUR 1.4 million from OSEO to develop inecalcitol ...
Hybrigenics obtains EUR 1.4 million from OSEO to develop inecalcitol for the treatment of prostate cancer More

April 13, 2007
Hybrigenics' Inecalcitol Shows High Level of Tolerance
Hybrigenics successfully performs first clinical trial More

February 7, 2006
Hybrigenics acquires worldwide rights to inecalcitol, a vitamin D analogue
Hybrigenics SA has acquired a license for the worldwide exclusive rights to inecalcitol, a synthetic analogue of vitamin D, for all clinical indications. More

Data


26,807
Tech investments
From our Online Data Service
17,301
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Mar 23€2.0MInternet services
Mar 23€1.5MInternet services
Mar 23€110.0MInternet commerce
Mar 21€1.9MBusiness applications
Mar 20€1.0MInternet commerce
Mar 20€12.0ME-Commerce

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.